PRESS RELEASE published on 03/27/2026 at 07:30, 4 months 6 days ago Inside Information / News release on accounts, results GenSight Biologics reported estimated full-year consolidated financial results for 2025, highlighting key regulatory milestones achieved and cash runway projection through December 2026 Financial Results Phase III Trial GenSight Biologics Cash Runway Regulatory Milestones
BRIEF published on 03/23/2026 at 09:53, 4 months 10 days ago Heights Capital Management exceeds 8% of GENSIGHT BIOLOGICS' capital Capital Increase Threshold Crossing GenSight Biologics Capital And Voting Rights Heights Capital
BRIEF published on 03/18/2026 at 10:20, 4 months 15 days ago GenSight Biologics finalizes its €1.7 million fundraising round Ordinary Shares Fundraising GenSight Biologics Gene Therapies Risk Factors
PRESS RELEASE published on 03/18/2026 at 10:15, 4 months 15 days ago Inside Information / Other news releases GenSight Biologics closes nearly €1.7 million fundraising for developing gene therapies in ophthalmology and CNS disorders. Contact: CFO Jan Eryk Umiastowski Fundraising Ophthalmology GenSight Biologics Gene Therapies CNS Disorders
BRIEF published on 03/10/2026 at 09:05, 4 months 23 days ago GenSight Biologics Secures €1.7 Million in Fresh Fundraising Fundraising Clinical Trials Gene Therapy Financial Strategy Shares And Warrants
PRESS RELEASE published on 03/10/2026 at 09:00, 4 months 23 days ago Inside Information / News release on accounts, results GenSight Biologics successfully raises nearly €1.7 million, continuing its fundraising activities for gene therapies. Company's CEO and CFO comment on operational milestones and future plans Fundraising GenSight Biologics Gene Therapies Cash Runway Operational Milestones
BRIEF published on 03/09/2026 at 07:35, 4 months 24 days ago GenSight Biologics: Update on Early Access Programs and the REVISED Study Gene Therapy GenSight Biologics Early Access Optic Neuropathy REVISED STUDY
BRIEF published on 03/09/2026 at 07:35, 4 months 24 days ago GenSight Biologics Updates on Early Access Programs and REVISE Study GenSight Biologics Leber Hereditary Optic Neuropathy Early Access Programs GS010/LUMEVOQ® REVISE Study
PRESS RELEASE published on 03/09/2026 at 07:30, 4 months 24 days ago Inside Information / Other news releases GenSight Biologics provides updates on GS010/LUMEVOQ® early access programs and the ongoing REVISE study for treating LHON. Approvals, enrollments, and expansions announced in France, Israel, and the USA GenSight Biologics LHON Early Access Programs GS010/LUMEVOQ REVISE Study
BRIEF published on 02/18/2026 at 07:35, 5 months 12 days ago GenSight Biologics Strengthens its Regulatory Team Phase III Trial Regulatory Affairs Key Appointments GenSight Biologics Gene Therapies
Published on 08/01/2026 at 01:20, 1 day 16 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 1 day 16 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 1 day 17 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 07/31/2026 at 23:20, 1 day 18 hours ago Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.
Published on 08/02/2026 at 08:15, 9 hours 38 minutes ago Holcim signs agreement to divest its business in the Philippines
Published on 08/01/2026 at 16:35, 1 day 1 hour ago HIZENERGY Enters Global Top Tier with BloombergNEF Tier 1 Listing
Published on 07/31/2026 at 19:55, 1 day 21 hours ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA Reaches Agreement with Financing Partners on Extension of Standstill Agreement and Continuation of Restructuring Process
Published on 07/31/2026 at 19:05, 1 day 22 hours ago Eurobattery Minerals presents the Q2 report for 2026 as the Company accelerates the development of the San Juan tungsten project
Published on 07/31/2026 at 21:00, 1 day 20 hours ago Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:13, 1 day 22 hours ago Covivio - Information on Treasury shares transactions between July 29th, 2026 and July 31st, 2026
Published on 07/31/2026 at 18:30, 1 day 23 hours ago Covivio Hotels - 2026 Half-year financial report
